Skip to main content
. 2020 Nov 7;37(5):705–711. doi: 10.5114/ada.2020.100481

Table 5.

Results of post-hoc (Tukey or Dunn’s) test for each study group: IL-6 and IL-22. Only statistically significant results presented

Study group Multiple comparisons P-value
IL-6 [pg/ml]:
Adalimumab 0 vs. 12 0.0006
0 vs. 24 0.0208
0 vs. 36 0.0018
Etanercept 0 vs. 3 0.0046
Infliximab 0 vs. 36 0.0132
Ustekinumab 3 vs. 12 0.0137
IL-22 [pg/ml]:
Adalimumab 0 vs. 12 0.0247
0 vs. 24 0.0004
0 vs. 36 0.0040
Infliximab 0 vs. 36 0.0235